

## PHARMACEUTICAL CARE BLOCK DIAGRAM




FIG. 1A

02/19

PHARMACEUTICAL CARE BLOCK DIAGRAM




FIG. 1B

FIG. 1C

03/19

## PATIENT CURRENT THERAPY




FIG. 2

04/19

DRUG USE EVALUATION




FIG. 3

0900278-10400

05/19

PHARMACIST CARE PLAN




FIG. 4

09500278 104001

06/19

PATIENT-BASED QUERY




FIG. 5

07/19

## DISEASE-BASED QUERY




FIG. 6

08/19

DRUG-BASED QUERY




FIG. 7



09/19

DRUG CLASS-BASED QUERY




FIG. 8

10/19

ADVERSE REACTION-BASED QUERY




FIG. 9

09900278.101001

11/19

PCCF--FORM




FIG. 10

09500278-101001

12/19

HCFA 1500 - FORM




FIG. 11

13/19

HUMANISTIC OUTCOME SURVEYS




FIG. 12

09/00278 10:004

14/19

PATIENT QUERY PROCESS




FIG. 13

15/19

DRUG UTILIZATION REPORT




FIG. 14

16/19

THERAPY ASSESSMENT REPORTS




FIG. 15



17/19

CLINICAL OUTCOME REPORT




FIG. 16

18/19

ETREBY COMPUTER COMPANY, INC.  
2145 W. LA PALMA AVE.  
ANAHEIM, CA 92801  
(714)533-1308

DATE PRINTED: 2/10/99

PHARMACIST CARE PLAN

PATIENT: xxxxxxx

PHYSICIAN: xxxxx  
PHARMACIST: xxxxx  
SERVICE DATE: 2/22/98

DISEASE/TASK: ASTHMA

PROBLEMS/NEEDS:

- 1-WAKING UP AT NIGHT DUE TO SYMPTOMS OF ASTHMA >TWICE A MONTH.
- 2-INCREASED USE OF SHORT ACTING BETA AGONISTS (.QID).
- 3-LONG-TERM OVERUSE OF BETA AGONISTS (>1 CANISTER/MONTH).
- 4-POOR TOLERANCE TO PHYSICAL ACTIVITY.

GOALS:

- PREVENT CHRONIC, TROUBLESOME SYMPTOMS (COUGHING OR BREATHLESSNESS).
- 1-MAINTAIN (NEAR) "NORMAL" PULMONARY FUNCTION.
  - 2-MAINTAIN NORMAL ACTIVITY LEVELS INCLUDING EXERCISE.
  - 3-PREVENT EXACERBATIONS & MINIMIZE THE NEED FOR ER OR HOSPITAL VISITS.
  - 4-MEET PATIENT'S EXPECTATIONS OF, & SATISFACTION WITH ASTHMA CARE.

PLAN:

- 1-CONTINUE QUICK-RELIEF MEDICATION (E.G. SA INHALED B2-AGONIST) PRN SYMPTOMS.
- 2-ADD A DAILY INFLAMMATORY (LOW DOSE STEROID, CROMOLYN, OR NEDOCROMIL).
- 3-MONITOR ADHERENCE TO BOTH CLASSES OF MEDICATIONS.
- 4-IMPLEMENT ENVIRONMENTAL CONTROL MEASURES.

MONITORING PARAMETERS:

SYMPTOMS	COUGHING AND WHEEZING	PHYSICAL ACTIVITY LIMITATION	EXACERBATIONS	NOCTURNAL AWAKENING LAST 30 DAYS
	2OR<TIMES/WK	SLIGHTLY LIMITED	MILD	2-4 TIMES
DISEASE ISSUES	TYPE OF ASTHMA	SEVERITY CLASSIFICATION	MISSED SCHOOL/WORK LAST 30 DAYS	E.R. OR HOSPITAL VISITS LAST 30 DAY
	ALLERGIC (EXTRINSIC)	MILD PERS	ONE TIME	NONE
MEASUREMENTS	PEFR(% OF PERSONAL BEST)	PEFR VARIABILITY(%)	FREQUENCY OF QUICK-RELIEF MEDS	CANISTERS OF QUICK- QUICK-RELIEF MEDS/MO.
	<OR=80	10-20	QID	>1 BUT <2
ADHERENCE	TO QUICK RELIEF MEDICATIONS	TO ANTIINFLAMMATORY MEDICATIONS	TO LIFESTYLE ISSUES MEDICATIONS	TO ENVIRONMENTAL CONTROL
	FAIR	POOR	GOOD	FAIR

10

FIG. 17A

00900278 101001

19/19

ETREBY COMPUTER COMPANY, INC.  
2145 W. LA PALMA AVE.  
ANAHEIM, CA 92801  
(714)533-1308

DATE PRINTED: 2/10/99

## PHARMACIST CARE PLAN

PATIENT: xxxxxxx

PHYSICIAN: xxxxx

PHARMACIST: xxxxx

SERVICE DATE: 2/22/98

DISEASE/TASK: ESSENTIAL HYPERTENSION

*PROBLEMS/NEEDS:*

- 1-IDENTIFY MAJOR RISK FACTORS.
- 2-DETERMINE PRESENCE OF TOD AN CCD.
- 3-BASED ON BP MEASUREMENTS DETERMINE BP CLASSIFICATION.
- 4-EVALUATE RISK STRATIFICATION AND IDENTIFY "RISK GROUP".
- 5-EXAMINE LIFESTYLE MODIFICATION ISSUES.
- 6-FOLLOW BP TREATMENT ALGORITHM AND INDIVIDUALIZE THERAPY.

*GOALS:*

- 1-TO REDUCE MORBIDITY AND MORTALITY BY THE LEAST INTRUSIVE MEANS POSSIBLE.
- 2- TO ACHIEVE AND MAINTAIN BP BELOW 140/90.
- 3-TO CONTROL OTHER MODIFIABLE RISK FACTORS FOR CVD.
- 4-TO PREVENT STROKE, PRESERVE RENAL FUNCTION, AND PREVENT OR SLOW HEART FAILURE PROGRESSION.

*PLAN:*

- 1-IDENTIFY KNOWN CAUSES OF HIGH BLOOD PRESSURE.
- 2-ASSESS THE PRESENCE OF TOD AND CVD, THE EXTENT OF THE DISEASE, AND THE RESPONSE TO THE THERAPY.
- 3-IDENTIFY OTHER CARDIOVASCULAR RISK FACTORS OR CONCOMITANT DISORDERS THAT MAY DEFINE PROGNOSIS AND GUIDE TREATMENT.
- 4-FOLLOW LIFESTYLE MODIFICATION GUIDELINES

*MONITORING PARAMETERS:*

<i>SYMPTOMS</i>	<i>SMOKING</i>	<i>ALCOHOL INTAKE</i>	<i>DYSLIPIDEMIA</i>	<i>OBESITY</i>
	NO	YES	YES	YES
<i>DISEASE ISSUES</i>	<i>FAMILY HISTORY OF CVD</i>	<i>TARGET ORGAN DAMAGE</i>	<i>CLINICAL CARDIOVASCULAR DISEASE</i>	<i>DIABETES</i>
	YES	NO	NO	YES
<i>MEASUREMENTS</i>	<i>SYSTOLIC BLOOD PRESSURE</i>	<i>DIASTOLIC BLOOD PRESSURE</i>	<i>BLOOD PRESSURE CLASSIFICATION</i>	<i>RISK STRATIFICATION</i>
	160-179	100-109	STAGE 1	RISK GROUP C
<i>ADHERENCE</i>	<i>DRUG THERAPY</i>	<i>DIET</i>	<i>EXERCISE</i>	<i>LIFE-STYLE ISSUES</i>
	FAIR	FAIR	GOOD	POOR

FIG. 17B

05900278 104004